Cardiff Oncology/$CRDF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cardiff Oncology
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Ticker
$CRDF
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
33
ISIN
US14147L1089
Website
Cardiff Oncology Metrics
BasicAdvanced
$201M
-
-$0.92
1.56
-
Price and volume
Market cap
$201M
Beta
1.56
52-week high
$5.64
52-week low
$2.01
Average daily volume
1.1M
Financial strength
Current ratio
6.223
Quick ratio
6.041
Long term debt to equity
0.903
Total debt to equity
1.913
Profitability
EBITDA (TTM)
-51.705
Gross margin (TTM)
-6,598.64%
Net profit margin (TTM)
-8,322.66%
Operating margin (TTM)
-8,875.64%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-41.00%
Return on equity (TTM)
-74.15%
Valuation
Price to revenue (TTM)
273.254
Price to book
2.83
Price to tangible book (TTM)
2.83
Price to free cash flow (TTM)
-3.752
Free cash flow yield (TTM)
-26.65%
Free cash flow per share (TTM)
-80.49%
Growth
Revenue change (TTM)
-3.77%
Earnings per share change (TTM)
1.99%
3-year revenue growth (CAGR)
17.59%
10-year revenue growth (CAGR)
7.08%
3-year earnings per share growth (CAGR)
3.02%
10-year earnings per share growth (CAGR)
-35.70%
What the Analysts think about Cardiff Oncology
Analyst ratings (Buy, Hold, Sell) for Cardiff Oncology stock.
Cardiff Oncology Financial Performance
Revenues and expenses
Cardiff Oncology Earnings Performance
Company profitability
Cardiff Oncology News
AllArticlesVideos
Cardiff Oncology Names Roger Sidhu as Medical Chief
Market Watch·3 days ago
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
GlobeNewsWire·3 days ago
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cardiff Oncology stock?
Cardiff Oncology (CRDF) has a market cap of $201M as of June 20, 2025.
What is the P/E ratio for Cardiff Oncology stock?
The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of June 20, 2025.
Does Cardiff Oncology stock pay dividends?
No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Cardiff Oncology dividend payment date?
Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiff Oncology?
Cardiff Oncology (CRDF) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.